



Immune Design
Investor Relations Department
Immune Design Corp. Attn:
Accounts Payab
601 Gateway Blvd. Suite 250
South San Francisco, CA 94080
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: IMDZ

Last Trade:	3.75
Trade Time:	4:00 PM ET Dec 12, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.55 - 13.05
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Dec 10, 2017](#)
[Combination of G100 with KEYTRUDA \(pembrolizumab\) Triggers Robust Systemic Responses in Follicular NHL Patients](#)
- [Nov 13, 2017](#)
[Immune Design to Present at Jefferies 2017 London Healthcare Conference](#)
- [Nov 7, 2017](#)
[Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates](#)
- [Nov 1, 2017](#)
[Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update](#)
- [Oct 27, 2017](#)
[Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- [Mar 7, 2017](#)
[Annual Report \(10-K\)](#)
- [Apr 26, 2017](#)
[Proxy Statement \(DEF 14A\)](#)
- [Nov 1, 2017](#)
[Quarterly Report \(10-Q\)](#)
- [Aug 2, 2017](#)
[Quarterly Report \(10-Q\)](#)
- [May 4, 2017](#)
[Quarterly Report \(10-Q\)](#)